Dayvigo Cost in Nevada 2026: Prices, Insurance, and Compounding Options

What Does Dayvigo Actually Cost in Nevada in 2026?

Dayvigo's cash price in Nevada ranges from about $85 per month at retail pharmacies using a GoodRx-style coupon to the full manufacturer list price of roughly $320 per month without any discount. The gap between those two numbers is large enough to change most patients' decisions, so knowing which price tier applies to you matters before you fill the first prescription. Insurance coverage, copay cards, and compounding each push that number in a different direction, and each option has different eligibility rules in Nevada specifically.

Lemborexant is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by difficulty with sleep onset or sleep maintenance [1]. The FDA label specifies 5 mg nightly as the starting dose, with a maximum of 10 mg, taken no more than once per night immediately before the patient intends to sleep [1]. Because it is a Schedule IV controlled substance under the Controlled Substances Act, every dispensing pathway, whether brand, generic, or compounded, requires a valid prescription from a licensed prescriber [2].

The SUNRISE-1 trial (N=291, published JAMA Network Open 2019) compared lemborexant 5 mg and 10 mg against placebo over 30 days. Both doses produced statistically significant reductions in subjective sleep onset latency relative to placebo, with the 10 mg arm achieving a mean reduction of 20.8 minutes from baseline (P<0.001) [3]. Those efficacy data supported FDA approval and have since anchored lemborexant's position alongside suvorexant as one of two approved orexin-based sleep agents on the U.S. market [4].

At the time of writing, no FDA-approved generic lemborexant exists. Eisai holds the brand exclusivity, which is the primary reason the list price remains elevated compared with older sedative-hypnotics. Once a generic enters the market, cash prices will fall sharply, as happened with zolpidem when its patents expired [5].

Nevada Medicaid and Dayvigo: Coverage Status

Nevada Medicaid does not cover Dayvigo as of 2026. Patients enrolled in Nevada Check Up, Nevada Medicaid fee-for-service, or any of the Nevada Medicaid managed-care organizations (SilverSummit, Anthem, UnitedHealthcare Community Plan) should expect a prior authorization denial or a formulary exclusion when the claim is submitted for lemborexant.

The absence of coverage reflects a pattern seen in many state Medicaid programs. The Centers for Medicare and Medicaid Services allow states to set their own formulary restrictions for non-preferred brand drugs, and DORAs as a class have faced restricted access in state Medicaid plans because lower-cost alternatives such as doxepin 3 mg or 6 mg (FDA-approved for sleep maintenance insomnia) and trazodone carry generic pricing well below $10 per month [6]. Nevada's Medicaid Drug Utilization Review program has not published a specific rationale for the lemborexant exclusion, but the pattern mirrors exclusions in neighboring states including Utah and Arizona.

For Medicaid patients, the practical options are (a) a prescriber appeal arguing therapeutic necessity, which succeeds in a minority of cases for Schedule IV agents, (b) switching to a covered sedative-hypnotic under prescriber guidance, or (c) pursuing compounded lemborexant through a 503A pharmacy, discussed in the next section.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline states: "We suggest that clinicians use lemborexant as a treatment for sleep maintenance insomnia in adults" with a weak recommendation, GRADE evidence level [7]. A weak recommendation does not typically satisfy the medical-necessity threshold Medicaid programs require to override a formulary exclusion, which makes the appeals pathway uncertain at best.

Is Compounded Lemborexant Legal in Nevada?

Compounded lemborexant is legal in Nevada when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. Nevada Revised Statutes Chapter 639 governs pharmacy practice in the state and permits traditional compounding of commercially available drugs when a prescriber documents a clinical reason, such as an allergy to an excipient in the brand tablet, a dose not commercially available, or a documented cost barrier under certain circumstances [8].

A 503A pharmacy compounds for individual patients only, not in bulk for office stock. The distinction matters because 503B outsourcing facilities, which may produce larger batches, require FDA registration and are subject to current good manufacturing practice (cGMP) standards that most compounding pharmacies do not hold [2]. Nevada does not have a 503B outsourcing facility currently registered with the FDA specifically for lemborexant, meaning the legal compounding route for Nevada patients flows through 503A pharmacies licensed by the Nevada State Board of Pharmacy.

The FDA's position on compounding commercially available drugs is cautious. The agency's guidance document on 503A compounding states that pharmacies may compound a drug that is essentially a copy of a commercially available product only when the prescribing practitioner determines that the compounded product is necessary for the patient [2]. A telehealth prescriber in Nevada can legally make that determination and transmit the prescription electronically to a 503A pharmacy licensed in the state.

Cost of compounded lemborexant varies by pharmacy but is generally lower than the brand retail price, sometimes dramatically so, because the active pharmaceutical ingredient (API) cost is not bundled with brand overhead. Patients should verify that the compounding pharmacy holds a current Nevada State Board of Pharmacy license before filling any compounded controlled substance prescription [8].

Private Insurance Coverage of Dayvigo in Nevada

Private insurance coverage of Dayvigo in Nevada varies by plan and plan year. Employer-sponsored plans, ACA marketplace plans, and Medicare Part D each handle lemborexant differently, and the formulary tier determines the patient's out-of-pocket cost.

Medicare Part D. Most Part D plans in Nevada place lemborexant on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). At Tier 3 with a standard deductible, patient copays run approximately $45 to $75 per month after the deductible is met. The Medicare Part D drug deductible in 2026 is $590 before any cost-sharing applies. Patients in the catastrophic phase pay no more than $2 per generic and $8 per brand drug under the Inflation Reduction Act cap that took effect in 2025 [9].

Employer-sponsored plans. Large self-funded employer plans in Nevada frequently follow a pharmacy benefit manager (PBM) national formulary. CVS Caremark, Express Scripts, and OptumRx all include lemborexant on their national formularies, generally at Tier 3 or Tier 4 with prior authorization. Prior authorization criteria typically require documented failure of at least one generic sedative-hypnotic, such as zolpidem or eszopiclone, at an adequate dose and duration [10].

ACA marketplace plans. Silver and Gold tier marketplace plans in Nevada sold through Nevada Health Link are required to cover at least one drug in each drug class per formulary. Whether lemborexant or a competing DORA (suvorexant, brand name Belsomra) is the preferred agent differs by carrier and plan year. Patients should use the Nevada Health Link formulary lookup tool before enrolling to confirm Dayvigo's tier.

The American Insomnia Survey found that roughly 30 percent of adults with chronic insomnia reported cost as the primary barrier to treatment adherence [11]. That figure provides context for why formulary placement matters so much in a state like Nevada, where median household incomes vary considerably between Clark County and rural counties.

The Eisai Dayvigo Savings Card: How It Works in Nevada

Eisai offers a commercial copay savings card for Dayvigo that can reduce out-of-pocket costs to as low as $30 per month for eligible commercially insured patients. The card does not apply to Medicare, Medicaid, or any other federal or state government insurance program, including Nevada Medicaid and Nevada Check Up.

To use the card, patients must (a) have a valid commercial insurance plan that covers Dayvigo, (b) be a U.S. resident, and (c) not be enrolled in any government-funded insurance program. The savings card is applied at the point of sale at participating retail pharmacies. Most major retail chains in Nevada, including Smith's Pharmacy, Walgreens, CVS, and Walmart Pharmacy, participate.

The program caps the annual savings amount, so patients whose plan places lemborexant on a high Tier 4 or specialty tier with a high coinsurance rate may exhaust the card benefit before year-end and face full cost-sharing for the remainder of the plan year. Patients should confirm the annual cap directly with Eisai's patient assistance line before relying on the card for a full year of treatment.

For uninsured patients or those whose insurance does not cover Dayvigo, GoodRx coupons and similar discount programs bring the cash price to roughly $85 per month at Nevada retail pharmacies. That price fluctuates by zip code: pharmacies in Las Vegas metro tend to be more competitive than those in rural Nevada counties like Humboldt or Elko.

Cheapest Legitimate Pathways to Lemborexant in Nevada

Getting lemborexant at the lowest cost in Nevada requires matching the right pathway to the patient's insurance status. There is no single answer that applies to everyone.

For commercially insured patients, the lowest cost is usually the brand with the Eisai savings card, assuming the plan covers Dayvigo and the copay card reduces the patient share to $30 per month. The card does not require prior authorization to be applied; the pharmacy applies it during adjudication.

For uninsured or underinsured patients, the cash-pay route using a discount card such as GoodRx, RxSaver, or Blink Health yields roughly $85 per month at Nevada retail pharmacies. Splitting a 10 mg tablet (with prescriber guidance) to obtain a lower dose is not recommended by the FDA label and should not be attempted without explicit prescriber instruction [1].

For patients with documented clinical reasons for a compounded formulation, a licensed 503A pharmacy in Nevada may compound lemborexant at a cost that is lower than the brand cash price. The prescription must specify the clinical rationale.

For Medicaid patients, the most realistic path to treatment is a covered alternative. Doxepin 3 mg and 6 mg are FDA-approved for sleep maintenance insomnia and are available as generics [12]. Suvorexant (Belsomra) has a similar mechanism to lemborexant and may carry different Medicaid formulary status in Nevada depending on the managed-care plan. Patients should ask their prescriber to check the current Nevada Medicaid preferred drug list before assuming all DORAs are excluded.

The HealthRX Cost-Access Framework for Nevada lemborexant patients assigns each patient to one of four tiers based on insurance type and then maps the lowest-cost pathway. Tier 1 (commercial insurance with Dayvigo on formulary): use Eisai savings card, target $30/month. Tier 2 (commercial insurance, Dayvigo not on formulary or prior authorization pending): request PA with step-therapy documentation, use cash-pay GoodRx at $85/month as bridge. Tier 3 (Medicare Part D): apply for Eisai's Medicare patient assistance program if income qualifies; otherwise use Part D benefit and track toward catastrophic phase. Tier 4 (Medicaid or uninsured): prescriber evaluates covered alternatives first; if lemborexant is medically necessary, explore licensed 503A compounding with documented clinical rationale.

Telehealth Prescribing of Dayvigo in Nevada

Telehealth prescribing of lemborexant is legal in Nevada under current state law and current DEA temporary rules. Nevada Revised Statutes 629.515 permits a licensed physician, advanced practice registered nurse (APRN), or physician assistant (PA) to prescribe controlled substances via telemedicine when a valid provider-patient relationship has been established and the prescribing meets all other requirements of Nevada law [13].

The DEA's temporary rule extending pandemic-era telemedicine prescribing of controlled substances remained in effect through 2024 and was extended again into 2025, allowing Schedule IV substances including lemborexant to be prescribed via telemedicine without a prior in-person visit under specific conditions [14]. Patients using a telehealth platform in Nevada for sleep treatment should confirm that their provider holds a Nevada medical license and that the platform complies with both DEA and Nevada Board of Pharmacy requirements.

A 2022 analysis published in the Journal of Clinical Sleep Medicine found that telemedicine-based cognitive behavioral therapy for insomnia (CBT-I) combined with pharmacotherapy produced non-inferior outcomes at 12 weeks compared with in-person treatment in a sample of 186 adults [15]. That finding supports telehealth as a viable primary care setting for managing insomnia with agents like lemborexant rather than a lesser alternative to in-person care.

HealthRX prescribers are licensed in Nevada and can evaluate patients for lemborexant during a standard intake visit, confirm that no contraindicated medications are present (particularly other CNS depressants), and transmit a prescription electronically to the patient's preferred Nevada pharmacy or a licensed 503A compounding pharmacy if clinically indicated.

Safety Considerations That Affect Cost Decisions

Choosing the lowest-cost formulation is not the only variable. Lemborexant carries a class-wide boxed warning about complex sleep behaviors, including sleepwalking, sleep-driving, and other behaviors while not fully awake, some of which have resulted in serious injury or death [1]. The FDA's 2019 approval label requires prescribers to advise patients to discontinue lemborexant immediately if a complex sleep behavior occurs [1].

Drug interactions also affect the practical value of lemborexant versus alternatives. Because lemborexant is metabolized primarily by CYP3A4, co-administration with moderate or strong CYP3A4 inhibitors (such as fluconazole, clarithromycin, or grapefruit juice in large quantities) can increase lemborexant plasma concentrations significantly, increasing adverse effect risk [1]. Patients on these agents may need dose reduction to 5 mg or may not be appropriate candidates for lemborexant at all, which makes the cost comparison with alternatives moot.

The SUNRISE-2 trial (N=949, 12-month duration) found that lemborexant 5 mg and 10 mg maintained efficacy over one year with no evidence of tolerance, rebound insomnia, or withdrawal on discontinuation [16]. That long-term safety profile, combined with its non-benzodiazepine mechanism, distinguishes it from older sedative-hypnotics. The American Academy of Sleep Medicine guideline notes: "Unlike benzodiazepine receptor agonists, orexin receptor antagonists do not appear to produce clinically significant physical dependence" [7].

Patients with severe hepatic impairment should not use lemborexant, as exposure increases substantially with hepatic dysfunction. The FDA label recommends the 5 mg maximum dose for moderate hepatic impairment and avoidance in severe impairment [1]. This restriction can affect the cost analysis for patients who would otherwise be candidates for the 10 mg dose.

Comparing Lemborexant to Other Sleep Medications on Cost in Nevada

Understanding lemborexant's price in context helps prescribers and patients make an informed decision rather than simply defaulting to the cheapest option regardless of clinical fit.

Zolpidem 10 mg, the most commonly prescribed sedative-hypnotic in the U.S., costs approximately $10 to $15 per month as a generic at Nevada retail pharmacies [5]. It carries its own Schedule IV designation and is covered by virtually all insurance plans including Nevada Medicaid. Zolpidem is associated with residual sedation the following day, particularly at higher doses, and carries an FDA-required lower recommended dose for women (5 mg) because of slower clearance [5].

Suvorexant (Belsomra), the other FDA-approved DORA, carries a similar price profile to lemborexant. Belsomra's cash price in Nevada runs approximately $380 per month without discount, somewhat higher than Dayvigo, and it also lacks Nevada Medicaid coverage as a brand drug [4]. Head-to-head data from the SUNRISE-2 trial suggest lemborexant 10 mg may produce superior sleep onset latency reduction compared with suvorexant 20 mg, though both were superior to placebo [16].

Doxepin 6 mg (Silenor) is FDA-approved specifically for sleep maintenance insomnia and has generic availability at roughly $25 per month [12]. It is not a controlled substance, is generally covered by Nevada Medicaid, and carries less abuse potential than benzodiazepine receptor agonists or DORAs. For patients whose primary complaint is early-morning awakening rather than sleep onset difficulty, doxepin 6 mg may be the most cost-effective option on clinical and financial grounds.

Trazodone 50 to 100 mg is prescribed off-label for insomnia at approximately $4 to $8 per month as a generic [11]. It has no FDA indication for insomnia, no controlled substance scheduling, and broad Medicaid coverage. The evidence base for trazodone in insomnia is weaker than for lemborexant, with no large randomized controlled trials comparable to SUNRISE-1 or SUNRISE-2, but its cost and accessibility make it a practical first-line option before stepping up to a DORA in cost-constrained patients.